Evolus, Inc. (EOLS) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 50.24
30Y Low4.0·High124.0
ROE
↑
N/A
—
5yr avg: -703.7%
30Y Low-259%·High-113%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EOLS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Evolus, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $437M | $429M | $685M | $599M | $421M | $324M | $113M | $344M | $290M | — | — |
| Enterprise Value | $538M | $530M | $728M | $663M | $442M | $253M | $149M | $330M | $214M | — | — |
| P/E Ratio → | -8.29 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.47 | 1.44 | 2.57 | 2.97 | 2.83 | 3.25 | 2.00 | 9.84 | — | — | — |
| P/B Ratio | — | — | 123.99 | — | 22.76 | 3.96 | — | 4.33 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EOLS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.78 | 2.73 | 3.28 | 2.97 | 2.53 | 2.64 | 9.46 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EOLS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Evolus, Inc. earns an operating margin of -12.7%. Operating margins have expanded from -24.4% to -12.7% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.9% | 64.9% | 68.5% | 69.5% | 60.4% | 56.3% | 67.6% | 77.1% | — | — | — |
| Operating Margin | -12.7% | -12.7% | -12.9% | -24.4% | -44.0% | -44.6% | -270.7% | -283.3% | — | — | — |
| Net Profit Margin | -17.4% | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | -288.3% | -257.8% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -913.1% | — | -148.3% | -1049.8% | -5016.6% | -113.3% | — | — | -819.6% |
| ROA | -22.5% | -22.5% | -23.9% | -33.6% | -34.2% | -20.1% | -72.5% | -43.7% | -28.9% | -3.9% | -25.3% |
| ROIC | -44.5% | -44.5% | -56.4% | -90.0% | -198.5% | -321.4% | -794.3% | -112.3% | — | -9.3% | -28.0% |
| ROCE | -23.5% | -23.5% | -22.2% | -36.2% | -39.4% | -38.8% | -125.0% | -51.7% | -87.0% | — | -84.3% |
EOLS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $101M ($155M total debt minus $54M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 23.54 | — | 4.02 | 0.91 | — | 1.22 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 7.79 | — | 1.11 | -0.87 | — | -0.17 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.91 | -1.91 | -1.66 | -3.45 | -6.33 | -32.50 | -14.51 | -12.21 | -53.23 | — | — |
EOLS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.90x means Evolus, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.54x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.33x to 1.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.90 | 1.90 | 2.40 | 2.33 | 2.17 | 3.10 | 0.71 | 6.23 | 17.88 | 0.34 | 0.00 |
| Quick Ratio | 1.54 | 1.54 | 2.21 | 2.10 | 1.76 | 3.07 | 0.69 | 5.97 | 17.88 | 0.34 | 0.00 |
| Cash Ratio | 0.71 | 0.71 | 1.38 | 1.30 | 1.16 | 2.54 | 0.60 | 5.31 | 17.66 | — | — |
| Asset Turnover | — | 1.32 | 1.14 | 1.07 | 0.84 | 0.39 | 0.27 | 0.15 | — | — | — |
| Inventory Turnover | 3.87 | 3.87 | 6.91 | 5.60 | 3.12 | 24.71 | 5.46 | 1.25 | — | — | — |
| Days Sales Outstanding | — | 67.18 | 65.36 | 55.14 | 55.13 | 53.67 | 62.49 | 111.42 | — | — | — |
EOLS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Evolus, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $64M | $62M | $57M | $56M | $50M | $34M | $28M | $24M | $24M | $19M |
Peer Comparison
Compare EOLS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EOLSYou | $437M | -8.3 | — | — | 64.9% | -12.7% | — | -44.5% | — |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 SKIN | $86M | -4.1 | 51.0 | 2.3 | 65.3% | -6.9% | -16.9% | -6.8% | 83.3 |
 INMD | $849M | 9.4 | 6.5 | 10.1 | 78.5% | 23.0% | 13.5% | 13.5% | 0.2 |
 AVAH | $2B | 7.4 | 9.8 | 14.8 | 33.1% | 10.9% | 621.9% | 15.1% | 4.6 |
 MLAB | $525M | 78.6 | 14.1 | 12.3 | 63.5% | 7.4% | 3.9% | 4.9% | 2.2 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
EOLS — Frequently Asked Questions
Quick answers to the most common questions about buying EOLS stock.
What is Evolus, Inc.'s P/E ratio?
Evolus, Inc.'s current P/E ratio is -8.3x. This places it at the 50th percentile of its historical range.
Is EOLS stock overvalued?
Based on historical data, Evolus, Inc. is trading at a P/E of -8.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Evolus, Inc.'s profit margins?
Evolus, Inc. has 64.9% gross margin and -12.7% operating margin.